Observational Safety Study of Etanercept (Enbrel) for Treatment of Psoriasis

• Status: Completed
• Trial end date: 2013-02-08
• Target enrollment: 0
• Participant gender: All

Summary

This is an observational safety study tracking psoriasis patients on etanercept (Enbrel) for 5 years.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Amgen
• Treatments: Etanercept

Criteria

Inclusion Criteria:

• Patients with plaque psoriasis

Exclusion Criteria:

• Prior exposure to any tumor necrosis factor (TNF)-inhibitor

• Patients for whom Enbrel is contraindicated

• Patients currently enrolled in or has not yet completed at least 30 days since ending other investigational drug study.